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OBJECTIVE—To assess chemerin levels and regulation in sera
and adipose tissue from women with polycystic ovary syndrome
(PCOS) and matched control subjects.
RESEARCH DESIGN AND METHODS—Real-time RT-PCR
and Western blotting were used to assess mRNA and protein
expression of chemerin. Serum chemerin was measured by
enzyme-linked immunosorbent assay. We investigated the in vivo
effects of insulin on serum chemerin levels via a prolonged
insulin-glucose infusion. Ex vivo effects of insulin, metformin,
and steroid hormones on adipose tissue chemerin protein pro-
duction and secretion into conditioned media were assessed by
Western blotting and enzyme-linked immunosorbent assay,
respectively.
RESULTS—Serum chemerin, subcutaneous, and omental adi-
pose tissue chemerin were signiﬁcantly higher in women with
PCOS (n  14; P  0.05, P  0.01). Hyperinsulinemic induction
in human subjects signiﬁcantly increased serum chemerin levels
(n  6; P  0.05, P  0.01). In adipose tissue explants, insulin
signiﬁcantly increased (n  6; P  0.05, P  0.01) whereas
metformin signiﬁcantly decreased (n  6; P  0.05, P  0.01)
chemerin protein production and secretion into conditioned
media, respectively. After 6 months of metformin treatment,
there was a signiﬁcant decrease in serum chemerin (n  21; P 
0.01). Importantly, changes in homeostasis model assessment–
insulin resistance were predictive of changes in serum chemerin
(P  0.046).
CONCLUSIONS—Serum and adipose tissue chemerin levels are
increased in women with PCOS and are upregulated by insulin.
Metformin treatment decreases serum chemerin in these women.
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olycystic ovary syndrome (PCOS), a common
endocrinopathy affecting 5–10% of women in the
reproductive age, is characterized by menstrual
dysfunction and hyperandrogenism and is
associated with insulin resistance and pancreatic -cell
dysfunction, impaired glucose tolerance (IGT), type 2
diabetes, dyslipidemia, and visceral obesity (1,2). The
consequent hyperinsulinemia is more prevalent in lean and
obese women with PCOS when compared with age- and
weight-matched normal women (3).
The metabolic syndrome is associated with excessive
accumulation of central body fat. As well as its role in
energy storage, adipose tissue produces several hormones
and cytokines termed ‘adipokines’ that have widespread
effects on carbohydrate and lipid metabolism. They appear
to play an important role in the pathogenesis of insulin
resistance, diabetes, and atherosclerosis (4). Furthermore,
it is apparent that accumulation of visceral adipose tissue
poses a greater cardiometabolic risk than subcutaneous
adipose tissue (5) as removal of visceral rather than
subcutaneous adipose tissue has been shown to improve
insulin sensitivity (6). Moreover, differences in gene ex-
pression of adipocyte-secreted molecules (adipokines)
suggest that there are inherent adipose tissue depot–
speciﬁc differences in the endocrine function of adipose
tissue. In relation to this, we have published data on the
increased levels of vaspin in women with PCOS (7); vaspin
is a recently described adipokine mainly formed in human
visceral adipose tissue that has insulin-sensitizing effects
(8).
Recently, Bozaoglu et al. (9) reported chemerin as a
novel adipokine, circulating levels of which signiﬁcantly
correlated with BMI, circulating triglycerides, and blood
pressure, features of the metabolic syndrome. In addition,
chemerin or chemerin receptor knockdown impaired dif-
ferentiation of 3T3-L1 cells and attenuated the expression
of adipocyte genes involved in glucose and lipid homeosta-
sis (10).
With the aforementioned in mind and the fact that there
is no literature with regards to chemerin in human adipose
tissue and its regulation, in study 1, we assessed circulat-
ing chemerin as well as mRNA expression and protein
levels of chemerin in subcutaneous and omental adipose
tissue depots in women with PCOS against age, BMI, and
waist-to-hip ratio (WHR) in matched control subjects.
Furthermore, we studied the in vivo (study 2) and ex
vivo effects of insulin on circulating chemerin levels via
a prolonged insulin-glucose infusion in humans and
primary adipose tissue explant cultures, respectively. In
study 3 we studied the effects of metformin therapy,
widely used in the treatment of PCOS in women, on
circulating chemerin levels in tandem with associated
changes to clinical, hormonal, and metabolic parame-
ters in the same cohort of PCOS in women. Additionally,
we studied the ex vivo effects of metformin and steroid
hormones in human primary adipose tissue explants.
RESEARCH DESIGN AND METHODS
Study 1. Seventy three subjects were recruited consecutively from the
infertility clinic in accordance with the inclusion/exclusion criteria (PCOS:
n  19; control subjects: n  54) as previously described (7); 62 subjects were
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DIABETES, VOL. 58, SEPTEMBER 2009 1971from a previous study (7). Of the 19 PCOS subjects recruited, ﬁve withdrew
before the study could be completed. In the control group, seven subjects did
not complete the study. From the remaining 47 control subjects, 14 control
subjects matched for age, BMI, and WHR were included in the ﬁnal analysis
(Table 1). Blood and adipose tissue samples were obtained as previously
described (7). Subcutaneous adipose tissue was obtained froma3c m
horizontal midline incision 3 cm above the symphysis pubis. Omental
adipose tissue was obtained by excisional biopsy from the greater omentum.
The local research ethics committee of University Hospitals Coventry and
Warwickshire NHS Trust approved the study, and all patients involved gave
their informed consent in accordance with the guidelines in The Declaration
of Helsinki 2000.
Study 2. We measured circulating chemerin in six (three men, three women)
healthy subjects [age: (mean  SD) 26.5  8 years, BMI: 23.2  2.5 kg/m
2]. All
subjects studied were nonsmokers and otherwise healthy. Women volunteers
had regular periods, no clinical or biochemical hyperandrogenism, and were
not taking any medications. Exclusion criteria for the study, as previously
described (7), included age over 40 years, known cardiovascular disease,
thyroid disease, neoplasms, current smoking, diabetes, hypertension (blood
pressure 140/90 mmHg), and renal impairment (serum creatinine 120
mol/l). None of these women were on any medication for at least 6 months
before the study, including oral contraceptives, glucocorticoids, ovulation
induction agents, antidiabetic and antiobesity drugs, or estrogenic, antiandro-
genic, or antihypertensive medication. The local research ethics committee of
University Hospitals Coventry and Warwickshire NHS Trust approved the
study, and all patients involved gave their informed consent in accordance
with the guidelines in The Declaration of Helsinki 2000. To account for the
possible diurnal variation in chemerin levels, we obtained a daily control
curve by measuring fasting chemerin levels at 30-min intervals from 0800 to
1000 h. Subsequently, chemerin levels were measured at 2-h intervals until
2400 h and then at 0400 h as well as at 30-min intervals from 0800 to 1000 h on
day 2. On the following day, the same subjects were subjected to a prolonged
insulin-glucose infusion for 26 h beginning at 0800 h. Insulin (Human Actrapid)
was administered intravenously as a priming dose of 0.04 units/kg followed by
continuous infusion of 0.5 mU  kg
1  min
1. By choosing this rate of insulin
infusion we expected to achieve hyperinsulinemia with an approximate four-
to sixfold elevation of basal insulinemia (11). Fasting blood samples were
drawn at 30-min intervals between 0800 and 1000 h on day 1 and day 2 of the
prolonged insulin-glucose infusion (the ﬁrst and the last2ho ft h einfusion).
Intermediate blood samples were taken at 2-h intervals until 2400 h and then
at 0400 h on day 2. Glucose levels were maintained between 4.0 and 6.0
mmol/l.
Study 3. Subjects were recruited and blood samples were obtained as
previously described (7). A treatment with metformin in an “off-label use”
was offered to all women with PCOS independently from the results of
insulin sensitivity testing, as per standard clinical practice. The study
design was approved by the local research ethics committee of the
University of Magdeburg, and written informed consent was obtained from
all participants in accordance with the guidelines in The Declaration of
Helsinki 2000.
Biochemical and hormonal analysis. Assays were performed using an
automated analyzer as previously described (7). The estimate of insulin
resistance by homeostasis model assessment (HOMA-IR) score was calcu-
lated as previously described (12). Circulating leptin and adiponectin levels
were measured with a coated-tube immunoradiometric assay kit (Diagnostic
Systems Laboratories, Sinsheim, Germany) and by a commercially available
RIA kit (Millipore, Watford, U.K.), respectively, according to manufacturer’s
protocol.
Chemerin levels in sera and conditioned media from human adipose tissue
explants were measured using a commercially available enzyme-linked immu-
nosorbent assay (ELISA) kit (R & D Systems, Abingdon, U.K.), according to
manufacturer’s protocol, with an intra-assay coefﬁcient of variation of less
than 9%.
Primary explant culture. Adipose tissue organ explants were cultured using
a protocol that was a modiﬁcation of the method described by Fried and
Moustaid-Moussa (13). Adipose tissue explants were cultured for 24 h with or
without the addition of insulin, testosterone, 17-estradiol, androstenedione,
dehydroepiandrosterone-sulfate (DHEA-S), or metformin, as previously de-
scribed (7).
Total RNA extraction and cDNA synthesis. Total RNA was extracted from
adipose tissue samples and cDNA synthesized as previously described (7).
RT-PCR. Quantitative PCR of chemerin was performed on a Roche Light
Cycler system (Roche Molecular Biochemicals, Mannheim, Germany) as
previously described (7). The sequences of the sense and antisense primers
used were chemerin (252 bp) 5	-AGACAAGCTGCCGGAAGAGG-3	 and 5	-
TGGAGAAGGCGAACTGTCCA-3	; -actin (216 bp) 5	-AAGAGAGGCATCCT-
CACCCT-3	 and 5	-TACATGGCTGGGGTCTTGAA-3	.
Western blotting. Protein lysates were prepared as previously described (7).
Protein samples (30 g/lane) containing SDS sample buffer (5 M urea, 0.17 M
SDS, 0.4 M dithiothreitol, and 50 mmol/l Tris-HCl, pH 8.0) were subjected to
SDS-PAGE (10% resolving gel) and transferred to polyvinylidene diﬂuoride
(PVDF) membranes (Millipore). PVDF membranes were blocked in Tris-
buffered saline (TBS) containing 0.1% Tween-20 and 5% BSA for 2 h. The PVDF
membranes were then incubated with polyclonal primary goat anti-human
antibody for chemerin (R & D Systems) (1:1,000 dilution) or monoclonal
primary rabbit anti-human antibody for -actin (Cell Signaling Technology,
Beverly, CA) (1:1,000 dilution) overnight at 4°C. The membranes were washed
thoroughly for 60 min with TBS 0.1% Tween before incubation with the
TABLE 1
Clinical, hormonal, and metabolic features of women with PCOS and control subjects
PCOS (n  14) Control subjects (n  14) Signiﬁcance
Age (years) 29.5 (28–38) 32.5 (29–35) NS
BMI (kg/m
2) 30.5 (27.8–30.9) 28.8 (28–30.5) NS
WHR 0.89 (0.78–0.99) 0.84 (0.81–0.96) NS
Glucose (mmol/l) 5.5 (4.8–6.0) 4.5 (4.3–5.2) P  0.01
Insulin (pmol/l) 78.9 (42.0–91.1) 57.3 (48.5–66.0) NS
HOMA-IR 3.0 (2.1–3.6) 2.0 (1.4–2.2) P  0.05
Cholesterol (mmol/l) 5.1 (4.1–5.7) 5.0 (4.8–5.5) NS
Triglycerides (mmol/l) 2.0 (1.5–2.3) 0.9 (0.7–1.4) P  0.01
Luteinizing hormone (IU/l) 7.0 (6.0–10.0) 6.0 (5.0–7.0) NS
Follicle-stimulating hormone (IU/l) 6.0 (6.0–7.0) 6.5 (5.0–8.0) NS
Prolactin (mU/l) 348.0 (305.0–387.0) 304.5 (211.0–322.0) NS
E2 (pmol/l) 353.5 (287.0–471.0) 174.5 (129.0–264.0) P  0.01
Progesterone (nmol/l) 1.6 (1.3–2.1) 2.2 (1.7–2.3) NS
17-OH-P (nmol/l) 2.5 (2.1–2.8) 2.0 (1.2–2.3) NS
Testosterone (nmol/l) 1.7 (1.5–2.1) 0.8 (0.6–0.9) P  0.01
Androstenedione (nmol/l) 15.6 (14.2–16.8) 6.3 (5.0–8.2) P  0.01
DHEA-S (mol/l) 5.9 (5.4–6.6) 4.5 (4.0–5.3) P  0.05
SHBG (nmol/l) 31.5 (26.7–35.2) 59.0 (47.7–66.0) P  0.01
FAI 19.5 (14.5–21.2) 3.9 (3.3–6.1) P  0.01
Leptin (ng/ml) 24.9 (19.7–29.0) 24.1 (19.3–28.8) NS
Adiponectin (g/ml) 5.67 (4.52–7.5) 6.27 (5.52–9.48) NS
Chemerin (ng/ml) 6.02 (5.96–6.04) 2.62 (1.96–3.23) P  0.01
Data are medians (interquartile range). Group comparison by Mann-Whitney U test. FAI  Testosterone (nmol/liter)/SHBG (nmol/liter) 

100. NS  not signiﬁcant. FAI, free androgen index; SHBG, sex hormone–binding globulin.
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(Dako, Ely, U.K.) (1:2,000) or secondary anti-rabbit horseradish peroxidase–
conjugated immunoglobulin (Dako) [1:2000], respectively, for1ha troom
temperature. Antibody complexes were visualized using chemiluminescence
(ECL; GE Healthcare, Little Chalfont, U.K.). Human chemerin protein (R &
D Systems) was used as positive control and water as negative control (data
not shown).
Statistics. Data were analyzed by Student’s t test, Mann-Whitney U test,
Kruskal-Wallis, or Friedman’s ANOVA (post hoc analysis: Dunn’s test) accord-
ing to the number of groups compared; P  0.05 was considered signiﬁcant.
For Western immunoblotting experiments, the densities were measured using
a scanning densitometer coupled to scanning software Scion Image (Scion
Corporation, Frederick, MD). Standard curves were generated to ensure
linearity of signal intensity over the range of protein amounts loaded into gel
lanes. Comparisons of densitometric signal intensities for chemerin and
-actin were made only within this linearity range. Spearman Rank correlation
was used for calculation of associations between variables; P  0.05 was
considered signiﬁcant.
RESULTS
Demographic data. Table 1 shows the anthropometric,
biochemical, and hormonal data in all subjects. Glucose,
HOMA, triglycerides, 17-estradiol (E2), testosterone, an-
drostenedione, DHEA-S levels, and free androgen index
were signiﬁcantly higher, whereas sex hormone–binding
globulin was signiﬁcantly lower in women with PCOS.
Serum chemerin levels were signiﬁcantly higher in
PCOS subjects than in control subjects (6.02 [5.96–6.04]
vs. 2.62 [1.96–3.23] ng/ml; P  0.01; Table 1). Serum
progesterone levels in all women conﬁrmed follicular
phase of the menstrual cycle.
mRNA expression and protein levels of chemerin in
normal and PCOS women. We detected chemerin mRNA
in adipose tissue of all subjects, and subsequent sequenc-
ing of the PCR products conﬁrmed gene identity. Real-time
RT-PCR analysis corrected over -actin showed a signiﬁ-
cant increase of chemerin expression in subcutaneous
(*P  0.05) and omental (**P  0.01) adipose tissue of
PCOS when compared with normal control subjects
(Fig. 1A). However, no signiﬁcant difference in
chemerin mRNA expression was observed when com-
paring corresponding omental with subcutaneous adi-
pose tissue in PCOS and normal subjects (Fig. 1A; P 
0.05). Changes noted at mRNA level were also reﬂected
at protein level (Fig. 1B).
Study 2: Effects of a prolonged insulin-glucose infu-
sion on serum chemerin levels. Insulin infusion resulted
in elevation of fasting insulinemia from 78.1  12.0 pmol/l
to 294.6  31.0 pmol/l. Insulin levels remained elevated
until the end of the prolonged insulin-glucose infusion
(366.0  37.0 pmol/l). Chemerin levels remained unaltered
throughout the control day from 2.06  0.08 ng/ml be-
tween 0800 and 1000 h to 1.92  0.07 ng/ml between 0800
and 1000 h the next day (Fig. 2; P  0.05).
There was a profound effect of insulin on chemerin
levels over 26 h of insulin infusion: from 2.54  0.32 ng/ml
between 0800 and 1000 h to 3.97  0.37 ng/ml between
0800 and 1000 h the following day (Fig. 2; *P  0.05). The
increase in chemerin levels was relatively acute approach-
ing maximal values at 4 h (Fig. 2; 5.08  0.27 ng/ml, **P 
0.01) and persisting throughout the entire period of
hyperinsulinemia.
Study 3: Effects of metformin treatment on serum
chemerin levels. Metformin treatment was started in 34
women with PCOS. Only 21 women completed the study
and were investigated after 6 months of metformin treat-
ment. The anthropometric, biochemical, and hormonal
data of PCOS subjects investigated in study 1 were not
signiﬁcantly different compared with the PCOS subjects
investigated in study 3. Reasons for subjects not complet-
ing study 3 were nausea and gastrointestinal side effects
(n  4), pregnancies (n  5), incompliance (n  2), and
loss of contact (n  2). After 6 months of metformin
treatment, there were signiﬁcant decreases in serum
chemerin, WHR, E2, testosterone, glucose, and HOMA-IR
(Table 2).
Dose-dependent effects of insulin, testosterone, 17-
estradiol, androstenedione, DHEA-S, and metformin
on chemerin protein production and secretion into
conditioned media from control human omental adi-
pose tissue explants. We found that chemerin protein
production and secretion into conditioned media was
signiﬁcantly increased dose dependently by insulin in
control human omental adipose tissue explants (Fig. 3;
*P  0.05 and **P  0.01, respectively). Interestingly,
metformin signiﬁcantly decreased chemerin protein pro-
duction and secretion into conditioned media in control
human omental adipose tissue explants (Fig. 4 and *P 
0.05 and **P  0.01, respectively). Similar results were
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FIG. 1. A: Chemerin mRNA expression relative to -actin was
signiﬁcantly increased in human subcutaneous (Sc) and omental
(Om) adipose tissue depots when comparing PCOS women (n  14)
with normal control subjects (n  14), using real-time RT-PCR. Data
are expressed as percent difference of median of human subcutane-
ous adipose tissue of normal control subjects. Each experiment was
carried out in three replicates. Group comparison by Kruskal-Wallis
ANOVA and post hoc Dunn’s test; *P < 0.05, **P < 0.01. B:
Densitometric analysis of chemerin immune complexes having nor-
malized to -actin revealed that protein levels of chemerin were
signiﬁcantly increased in human subcutaneous and omental adipose
tissue depots, respectively, when comparing all women with PCOS
with all normal control subjects. Data are expressed as percent
difference of median of normal control subjects. Each experiment
was carried out in three replicates. Group comparison by Kruskal-
Wallis ANOVA (post hoc analysis: Dunn’s test). *P < 0.05, **P <
0.01; PSL, phosphostimulated light units.
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explants (data not shown). With respect to gonadal and
adrenal steroids, no signiﬁcant effects on chemerin protein
production and secretion were observed (data not shown).
Association of chemerin with covariates. In study 1,
Spearman’s rank analyses demonstrated that serum and
subcutaneous and omental adipose tissue chemerin levels
were signiﬁcantly positively associated with BMI, WHR,
glucose, insulin, HOMA-IR, and circulating triglycerides
(P  0.05). However, when subjected to multiple regres-
sion analysis, none of these variables were predictive of
serum chemerin levels (P  0.05).
In study 3, we analyzed the correlation between the
change in serum chemerin levels before and after met-
formin therapy (chemerin) and the changes () in other
covariates (Table 3). Chemerin was signiﬁcantly posi-
tively associated with WHR, glucose, insulin, HOMA-
IR, and triglycerides. When subjected to multiple
regression analysis with WHR, glucose, insulin, HOMA-IR,
and triglycerides, only HOMA-IR was predictive of
changes in serum chemerin levels (Table 3), whereas other
models of multiple regression analysis revealed no other
signiﬁcant predictors of changes in serum chemerin levels
(see supplemental data, available in an online appendix at
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FIG. 2. Mean concentrations of chemerin in nanogram per milliliter in all subjects, before and after insulin infusion. Insulin infusion resulted in
elevation of fasting insulinemia from 78.1  12.0 pmol/l to 294.6  31.0 pmol/l. Insulin levels remained elevated until the end of the prolonged
insulin-glucose infusion (366.0  37.0 pmol/l). Data are means  SD. Group comparison by Student’s t test. *P < 0.05, **P < 0.01.
TABLE 2
Clinical, hormonal, and metabolic features of women with PCOS (n  21) before and after metformin treatment
Before metformin After metformin Signiﬁcance
Age (years) 28 (26.5–31.5) 28 (27.5–32.5) NS
BMI (kg/m
2) 32.8 (29.8–36.5) 31.4 (28.2–35.1) NS
WHR 0.82 (0.76–0.88) 0.80 (0.74–0.87) P  0.05
Glucose (mmol/l) 5.1 (4.7–5.5) 4.8 (4.4–4.9) P  0.01
Insulin (pmol/l) 70.0 (54.5–98.0) 60.0 (43.5–81.0) NS
HOMA-IR 2.1 (1.7–3.1) 1.6 (1.3–2.3) P  0.05
Cholesterol (mmol/l) 4.9 (4.1–5.3) 5.0 (4.0–5.4) NS
Triglycerides (mmol/l) 1.0 (0.7–1.9) 1.2 (1.0–1.7) NS
E2 (pmol/l) 329.8 (164.9–494.7) 207.1 (103.6–310.7) P  0.05
Testosterone (nmol/l) 1.8 (1.4–2.2) 1.3 (1.0–1.8) P  0.05
Androstenedione (nmol/l) 10.9 (8.0–14.0) 9.7 (7.6–12.4) NS
DHEA-S (mol/l) 4.4 (2.8–5.8) 5.4 (3.6–6.7) NS
SHBG (nmol/l) 27.0 (21.0–41.0) 25.0 (20.5–46.5) NS
FAI 6.2 (4.6–8.0) 5.2 (3.1–6.6) NS
Leptin (ng/ml) 26.5 (20.7–30.9) 25.1 (17.9–30.0) NS
Adiponectin (g/ml) 4.85 (4.14–6.88) 3.69 (2.91–5.55) NS
Chemerin (ng/ml) 6.36 (5.80–6.83) 2.19 (2.04–4.02) P  0.01
Data are medians (interquartile range). Group comparison by Mann-Whitney U test. FAI  Testosterone (nmol/liter)/SHBG (nmol/liter) 

100. NS  not signiﬁcant. FAI, free androgen index; SHBG, sex hormone–binding globulin.
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DISCUSSION
We present novel data showing a signiﬁcant increase of
serum and subcutaneous and omental adipose tissue
chemerin mRNA expression as well as protein levels in
women with PCOS. More importantly, we demonstrate the
potent and robust regulation of chemerin in vivo and ex vivo
by insulin as well as its modulation by metformin treatment.
Unfortunately, because of technical limitations in adipose
tissue procurement, we were unable to obtain sufﬁcient
amounts of sample/patient tissue to perform stromal vascu-
lar separation in adipose tissue depots. We could not account
for a potential adipocyte hypertrophy–related side effect.
These limitations not withstanding, adipose tissue from our
PCOS women, compared with control subjects, express
more chemerin.
PCOS have an increased incidence of IGT and type 2
diabetes (1,2). The higher serum and adipose tissue
chemerin levels in women with PCOS is of interest given
that it has recently been reported that IGT and type 2
diabetes Psammomys obesus animals (a unique polygenic
animal model for obesity and type 2 diabetes) had higher
adipose tissue chemerin levels than normal glucose–toler-
ant Psammomys obesus animals. In the same study,
signiﬁcant positive associations with BMI and circulating
triglycerides in normal glucose–tolerant human subjects
were noted (9). However, no data exists on chemerin and
its regulation in human adipose tissue. In our study, we
found signiﬁcant positive associations between circulating
chemerin as well as chemerin levels in subcutaneous and
omental adipose tissue with BMI, WHR, glucose, insulin,
HOMA-IR, and circulating triglycerides. However, it is
unlikely that either BMI or WHR are responsible for these
ﬁndings, as both groups were matched for these variables.
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FIG. 3. A: Dose-dependent effects of insulin (10
11 M, 10
9 M, 10
7 M) in the presence of 5 mmol/l D-glucose on chemerin net protein production
in control human omental adipose tissue explants at 24 h were assessed by Western blotting. Western blot analysis of protein extracts from
omental adipose tissue demonstrate that the antibody against chemerin and the antibody against -actin recognized bands with apparent
molecular weights of 18 kDa and 45 kDa, respectively (Fig. 3A, inserts). Densitometric analysis of chemerin immune complexes having normalized
to -actin, respectively, revealed that protein levels of chemerin were signiﬁcantly increased by insulin (10
9 M, 10
7 M) in control human
omental adipose tissue explants. Data are expressed as percent difference of median of basal. Each experiment was carried out with six different
samples from six different subjects in three replicates. Group comparison by Friedman’s ANOVA and post hoc Dunn’s test. *P < 0.05, **P < 0.01.
B: Dose-dependent effects of insulin (10
11 M, 10
9 M, 10
7 M) in the presence of 5 mmol/l D-glucose on chemerin secretion into conditioned media
from control human omental adipose tissue after 24 h were measured by ELISA. Chemerin secretion was signiﬁcantly increased (by 10
9 M, 10
7
M) from control human omental adipose tissue explants. Data are expressed as percent difference of median of basal. Each experiment was
carried out with six different samples from six different subjects in three replicates. Group comparison by Friedman’s ANOVA and post hoc Dunn’s
test. *P < 0.05, **P < 0.01.
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lations may be spurious, without causative signiﬁcance,
resulting from the simple fact that our PCOS women had
higher levels for all these parameters.
Importantly, in study 2 we derive novel observations of
a profound increase in chemerin levels by insulin in vivo.
This effect of insulin appears to be relatively acute, achiev-
ing a maximal effect 4 h after commencement of insulin
and persisting throughout the entire period of hyperinsu-
linemia. Furthermore, this is in agreement with our data
on the regulation of chemerin protein production ex vivo.
It is important to bear in mind that the regulation of
chemerin in adipose tissue is probably multifactorial.
Moreover, it would be of interest to know whether or not
the effects of insulin on chemerin production are also
applicable to other tissues given our in vivo data. Future
studies are needed to elucidate the role of other factors
that regulate chemerin production. Taken together, the
above ﬁndings could tentatively explain the increased
levels of chemerin seen in our insulin-resistant PCOS
subjects. Of secondary interest, there appears to be no
circadian variation in chemerin levels as depicted in Fig. 2.
It should be emphasized that the primary aim of this study
was not to investigate the circadian variation of chemerin.
In addition, our study utilized relatively small numbers of
subjects because of the challenge imposed by the pro-
longed insulin clamp study; hence, care needs to be
exercised in interpretation of these results.
More importantly, in study 3 we report for the ﬁrst time
that metformin (6 months treatment; 850-mg twice daily)
signiﬁcantly decreases circulating chemerin levels with a
concomitant decrease in insulin resistance in PCOS sub-
jects. Additionally, although the change in serum chemerin
levels were signiﬁcantly positively associated with
changes in WHR, glucose, insulin, HOMA-IR, and triglyc-
erides, when subjected to multiple regression analysis
only HOMA-IR was predictive of serum chemerin levels.
Taken together, we hypothesize that elevated chemerin
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FIG. 4. A: Dose-dependent effects of metformin (0.01, 0.1, and 2.00 g/ml) in the presence of 5 mmol/l D-glucose on chemerin net protein
production in control human omental adipose tissue explants at 24 h were assessed by Western blotting. Western blot analysis of protein extracts
from omental adipose tissue demonstrate that the antibody against chemerin and the antibody against -actin recognized bands with apparent
molecular weights of 18 kDa and 45 kDa, respectively (Fig. 4A, inserts). Densitometric analysis of chemerin immune complexes having normalized
to -actin, respectively, revealed that protein levels of chemerin were signiﬁcantly decreased by metformin (0.01, 0.1, and 2.00 g/ml) in control
human omental adipose tissue explants. Data are expressed as percent difference of median of basal. Each experiment was carried out with six
different samples from six different subjects in three replicates. Group comparison by Friedman’s ANOVA and post hoc Dunn’s test. *P < 0.05,
**P < 0.01. B: Dose-dependent effects of insulin (0.01, 0.1, and 2.00 g/ml) in the presence of 5 mmol/l D-glucose on chemerin secretion into
conditioned media from control human omental adipose tissue after 24 h were measured by ELISA. Chemerin secretion was signiﬁcantly
decreased (by 0.01, 0.1, and 2.00 g/ml) from control human omental adipose tissue explants. Data are expressed as percent difference of median
of basal. Each experiment was carried out with six different samples from six different subjects in three replicates. Group comparison by
Friedman’s ANOVA and post hoc Dunn’s test. *P < 0.05, **P < 0.01.
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resistance in our cohort of PCOS subjects. Furthermore, of
relevance, an elegant study by Bozaoglu et al. (9) describes
important ﬁndings that circulating chemerin levels in type
2 diabetes human subjects were not signiﬁcantly higher
than those in normal control subjects. Therefore, our
observations are timely as they may explain the ﬁndings by
Bozaoglu et al. (9), given that quite probably a proportion
of their type 2 diabetic study subjects may have been
taking metformin (Bozaoglu et al. had not reported the
medications taken by their type 2 diabetic subjects, with
metformin arguably being the most common ﬁrst-line oral
hypoglycemic therapy to treat type 2 diabetes employed by
most physicians in both developing as well as developed
countries. Therefore, our study highlights metformin ther-
apy as a confounding factor concerning the regulation of
circulating chemerin levels. This should alert investiga-
tors who are studying chemerin biology to consider this
in their analyses. In addition, this point may also apply
to other forms of antidiabetic therapy; hence, caution
needs to be exercised appropriately.
A limitation of our study may relate to the number of
subjects studied. However, obtaining BMI/WHR-matched
and menstrual cycle–synchronized blood and adipose tis-
sue samples from two sites impeded subject recruitment.
Our observations are highly consistent and signiﬁcant and
raise interesting questions on the mechanisms regulating
chemerin production. Moreover, a sample size as in our
study is only likely to detect differences that are enor-
mous/signiﬁcant. Finally, it should be emphasized that our
ﬁndings relate only to overweight women with PCOS, and
it would be of interest to perform this study with lean
women with PCOS.
In conclusion, we report novel ﬁndings of a signiﬁcant
increase of circulating and adipose tissue chemerin, a
novel adipokine, in women with PCOS as well as the
potent and robust regulation of chemerin by insulin in vivo
and ex vivo. More importantly, we present novel data that
metformin treatment signiﬁcantly decreases circulating
chemerin levels in women with PCOS. The physiologic and
pathologic signiﬁcance of our ﬁndings remain to be further
elucidated.
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TABLE 3
Linear regression analysis of variables associated with changes
in serum chemerin levels (before and after metformin treatment),
chemerin, in PCOS subjects (n  21)
Simple Multiple
Estimate P Estimate P
BMI (kg/m
2) 0.156 0.500 — —
WHR 0.486 0.026 0.293 0.329
Glucose (mmol/l) 0.510 0.018 0.338 0.234
Insulin (pmol/l) 0.503 0.020 0.387 0.205
HOMA-IR 0.772 0.010 0.628 0.046
Cholesterol (mmol/l) 0.276 0.226 — —
Triglycerides (mmol/l) 0.490 0.024 0.456 0.107
E2 (pmol/l) 0.240 0.327 — —
Testosterone (nmol/l) 0.130 0.576 — —
Androstenedione (nmol/l) 0.039 0.867 — —
DHEA-S (mol/l) 0.055 0.814 — —
SHBG (nmol/l) 0.236 0.304 — —
FAI 0.224 0.330 — —
Leptin (ng/ml) 0.003 0.989 — —
Adiponectin (g/ml) 0.026 0.911 — —
In multiple linear regression analysis, values included were WHR,
glucose, insulin, HOMA-IR, and triglycerides. FAI, free androgen
index; SHBG, sex hormone–binding globulin.
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